Global markets are sending mixed signals right now. Inflation paths differ across Europe and Asia, central banks are weighing their next moves and growth indicators vary from Germany to China. In this kind of backdrop, stocks with healthy balance sheets and strong expected earnings growth can offer a more focused way to seek opportunity. That is exactly what the Healthy high growth potential screener aims to surface. It filters for companies that analysts expect to grow earnings over the next 3 years while keeping financial risk in check. This article highlights 3 of the stocks from that screener.

Sanmina (SANM)

Overview: Sanmina is a global electronics manufacturing and engineering partner that designs, builds, and services complex hardware for original equipment manufacturers across sectors such as industrial, medical, defense, automotive, communications networks, and cloud infrastructure. It supports customers from early product design through high volume production, logistics, and after-market repair.

Operations: Sanmina generates most of its revenue from Integrated Manufacturing Solutions at about US$11.0b, with a further US$1.9b from Components, Products and Services, while also recording intersegment revenue adjustments of roughly US$139.2m.

Market Cap: US$9.8b

Sanmina provides direct exposure to the build out of AI and cloud infrastructure. The planned ZT Systems acquisition and investments in automation and advanced circuit board capacity are intended to support higher margins, although customer concentration and execution risk around large acquisitions and global supply chains are important to watch. A P/E that is below peer averages and analyst price targets that sit above the current share price are often interpreted as indicating potential upside, depending on how forecasts develop. The full story for Sanmina, including key margin and balance sheet risks, sits beneath those headline numbers.

Sanmina’s lower P/E and AI infrastructure exposure suggest the market may be underpricing what sits behind its headline numbers. Get the full picture with the 3 key rewards and 2 important warning signs

Corcept Therapeutics (CORT)

Overview: Corcept Therapeutics focuses on treatments for serious hormone related and cancer conditions, led by Korlym for Cushing’s syndrome and a growing pipeline of selective cortisol modulators like relacorilant and miricorilant for metabolic, neurologic and oncologic diseases.

Market Cap: US$12.8b

Corcept Therapeutics has caught attention because its core Cushing’s business is now being joined by Lifyorli in ovarian cancer and a broader cortisol modulator pipeline, which together could reduce dependence on a single product and support the revenue growth that analysts are forecasting. At the same time, key risks include patent litigation around Korlym, pricing pressure as generics and payers push for discounts, and the fact that profit margins recently declined from 18.4% to 6.5% despite strong guidance upgrades. For investors watching high growth healthcare stocks, Corcept’s mix of rapid revenue growth forecasts, experienced management, and ongoing regulatory and legal overhangs makes it a complex story that may warrant closer examination.

Corcept Therapeutics sits at the crossroads of expanding cortisol therapies and fresh regulatory questions, with recent margin pressure masking what might come next in the 1 key reward and 1 important warning sign.

Coursera (COUR)

Overview: Coursera is a global online learning platform that offers guided projects, short courses, professional certificates, and full degree programs in fields like business, data science, technology, and computer science to individuals, companies, universities, and governments.

Operations: Coursera generates about US$549.9m from its Consumer segment including Degrees and US$335.5m from its Enterprise segment.

Market Cap: US$1.5b

Coursera gives you direct exposure to the shift toward online skills training and micro credentials, with high growth expectations as revenue is forecast to rise much faster than the broader US market and earnings are projected to move from losses toward meaningful profitability. The Udemy merger and the US$100m LearnVector investment are central to its push into AI powered learning, larger recurring subscription streams, and higher margin enterprise contracts. However, they also bring integration risk, heavier external funding, and recent shareholder dilution. For investors willing to accept current losses and a weaker balance sheet in return for scale, AI driven products, and a much larger addressable market, Coursera stands out as a high growth but higher risk candidate within this screener.

Coursera’s AI powered learning push and the Udemy merger could reshape its growth path, yet the real story lies in the analyst forecasts for Coursera, which may reveal how today’s dilution and balance sheet pressure really fit.

The three stocks in this Healthy high growth potential idea are just a starting point, with the full screen surfacing 259 more companies that analysts expect to grow earnings strongly while keeping balance sheets in reasonable shape through the Healthy high growth potential screener. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter most to you so you can focus on the highest conviction opportunities for your watchlist.

Take Control of Your Investment Journey

If Corcept Therapeutics or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Curious To Seek Fresh Alternatives

Fresh ideas move first. Stocks can break out, lose momentum, or get caught flying under the radar for now. Scan these curated shortlists before the edge drops away and act now.

• Seize potential income from resilient payers by scanning a curated pool of 9 dividend fortresses that aim to keep cash flows and balance sheets front and center.
• Track powerful structural trends inside energy and infrastructure by reviewing 35 power grid technology and infrastructure stocks that may benefit as grids modernize and capital spending shifts.
• Spot early movers at the crossroads of medicine and AI with 41 healthcare AI stocks that filter for quality fundamentals alongside high impact technology use cases.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.